Patent intelligence · US
US 12239712
Combination therapy for the treatment of liver disease
Combination therapy for the treatment of liver disease
Patent details — US 12239712
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 4, 2025
- Expiration
- Feb 27, 2045
- Applicant
- GALMED RESEARCH AND DEVELOPMENT LTD
- Claims
- 16
- CPC classes
- A61K, A61K31/192, A61K31/198, A61K31/53
Quick answer
US 12239712 (Combination therapy for the treatment of liver disease) is held by GALMED RESEARCH AND DEVELOPMENT LTD. Status: granted. Granted Mar 4, 2025. Expires Feb 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GALMED RESEARCH AND DEVELOPMENT LTD
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/192, A61K31/198, A61K31/53, A61K31/575, A61K31/662
More from GALMED RESEARCH AND DEVELOPMENT LTD
Related pharmaceutical patents in our USPTO index.
-
US 11571431
Aramchol salts
granted -
US 11197870
Treatment for hepatic fibrosis
granted -
US 11166964
Treatment for modulating gut microbiota
granted -
US 10849911
Low dose compositions of Aramachol salts
granted -
US 8975246
Bile acid or bile salt fatty acid conjugates
granted -
US 8110564
Bile acid or bile salt fatty acid conjugates
granted -
US 7501403
Bile acid or bile salt fatty acid conjugates
granted
Frequently asked questions
What is US patent 12239712?
US 12239712 (Combination therapy for the treatment of liver disease) is held by GALMED RESEARCH AND DEVELOPMENT LTD. Status: granted. Granted Mar 4, 2025. Expires Feb 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12239712?
GALMED RESEARCH AND DEVELOPMENT LTD is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does US 12239712 expire?
Our index shows an expiration date of Feb 27, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.